WuXi Biologics and HanchorBio Inc. have announced a strategic collaboration aimed at accelerating the development and manufacturing of multiple next-generation bi- and multi-functional fusion protein programs from HanchorBio’s pipeline. The partnership brings together WuXi Biologics’ global contract research, development, and manufacturing capabilities with HanchorBio’s proprietary Fc-Based Designer Biologics (FBDB™) platform, which is focused on advancing innovative immunotherapies for oncology and autoimmune diseases.
Under the terms of the agreement, WuXi Biologics will provide integrated, end-to-end biologics services to support HanchorBio’s fusion protein programs. These services include cell line development, process and bioassay development, drug product formulation development, and current Good Manufacturing Practice (GMP) manufacturing. The collaboration is designed to improve chemistry, manufacturing, and controls (CMC) efficiency, accelerate clinical translation, and enable scalable, globally compliant manufacturing as HanchorBio advances multiple assets toward clinical development.
For HanchorBio, the partnership aligns with its strategy to move platform-derived, multi-asset pipelines forward with greater speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics’ experience in complex biologics and its global quality systems, HanchorBio aims to shorten development timelines while maintaining flexibility across several parallel clinical programs.
WuXi Biologics brings a strong track record in supporting advanced therapeutic modalities, including bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, the company’s integrated platform supported 945 active projects, with approximately 60% involving bi- or multi-specific antibodies, ADCs, and fusion proteins. This extensive experience is complemented by proprietary technology platforms such as WuXia™ TrueSite, a targeted integration-based CHO cell line platform, and WuXiHigh™, a high-throughput formulation development platform, both designed to enhance development speed, product quality, and manufacturing scalability.
The collaboration also supports HanchorBio’s continued expansion of its FBDB™ platform, which enables the rational design of multi-functional fusion proteins intended to modulate both innate and adaptive immune responses. By combining discovery innovation with industrial-scale execution, the partnership is expected to strengthen HanchorBio’s ability to advance its oncology and autoimmune disease programs into global clinical development.
Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, said the collaboration reflects HanchorBio’s confidence in WuXi Biologics’ end-to-end capabilities for developing complex biologics. He noted that leveraging WuXi’s technology platforms and manufacturing expertise could help accelerate the delivery of transformative therapies to patients worldwide.
Dr. Scott Liu, Founder, Chairman, and Chief Executive Officer of HanchorBio, added that execution speed, manufacturing reliability, and scalability are critical as the company advances multiple fusion protein programs. He described WuXi Biologics as a strong strategic partner capable of supporting the translation of platform-driven innovation into high-quality clinical and commercial assets.